ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, announced its participation in two upcoming investor conferences in December 2024. The company will join a fireside chat at the 7th Annual Evercore HEALTHCONx Conference on December 4 at 2:35 p.m. ET, and participate in the 'Novel Mechanisms in Oncology II' panel at Citi's 2024 Global Healthcare Conference on December 5 at 11:00 a.m. ET. Live webcasts will be accessible through ORIC's website, with replays available for 90 days after the events.
ORIC Pharmaceuticals (Nasdaq: ORIC), una compagnia oncologica in fase clinica, ha annunciato la sua partecipazione a due prossime conferenze per investitori nel dicembre 2024. L'azienda parteciperà a una chiacchierata informale al 7° Annual Evercore HEALTHCONx Conference il 4 dicembre alle 14:35 ET e parteciperà al panel 'Novel Mechanisms in Oncology II' alla Citi's 2024 Global Healthcare Conference il 5 dicembre alle 11:00 ET. Le trasmissioni dal vivo saranno accessibili attraverso il sito web di ORIC, con le registrazioni disponibili per 90 giorni dopo gli eventi.
ORIC Pharmaceuticals (Nasdaq: ORIC), una compañía de oncología en etapa clínica, anunció su participación en dos próximas conferencias para inversores en diciembre de 2024. La empresa se unirá a una charla informal en la 7ª Conferencia Anual Evercore HEALTHCONx el 4 de diciembre a las 2:35 p.m. ET, y participará en el panel 'Novel Mechanisms in Oncology II' en la Citi's 2024 Global Healthcare Conference el 5 de diciembre a las 11:00 a.m. ET. Las transmisiones en vivo estarán disponibles a través del sitio web de ORIC, con repeticiones accesibles durante 90 días después de los eventos.
ORIC Pharmaceuticals (Nasdaq: ORIC), 임상 단계의 항암제 회사가 2024년 12월에 열리는 두 개의 투자자 회의에 참여한다고 발표했습니다. 회사는 12월 4일 오후 2시 35분 ET에 제7회 Evercore HEALTHCONx 컨퍼런스에서 원탁 대화에 참여하고, 12월 5일 오전 11시 ET에 Citi의 2024년 글로벌 헬스케어 컨퍼런스에서 'Novel Mechanisms in Oncology II' 패널에 참여할 예정입니다. 생중계는 ORIC 웹사이트를 통해 접근할 수 있으며, 이벤트 후 90일 동안 다시 볼 수 있습니다.
ORIC Pharmaceuticals (Nasdaq: ORIC), une entreprise de cancérologie en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs en décembre 2024. L'entreprise se joindra à une discussion informelle lors de la 7e Conférence Annuelle Evercore HEALTHCONx le 4 décembre à 14h35 ET et participera au panel 'Novel Mechanisms in Oncology II' lors de la Citi's 2024 Global Healthcare Conference le 5 décembre à 11h00 ET. Les webcasts en direct seront accessibles via le site web d'ORIC, avec des rediffusions disponibles pendant 90 jours après les événements.
ORIC Pharmaceuticals (Nasdaq: ORIC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei kommenden Investorenkonferenzen im Dezember 2024 angekündigt. Das Unternehmen wird am 4. Dezember um 14:35 Uhr ET an einem Fireside-Chat auf der 7. jährlichen Evercore HEALTHCONx-Konferenz teilnehmen und am 5. Dezember um 11:00 Uhr ET am Panel 'Novel Mechanisms in Oncology II' auf der Citi's 2024 Global Healthcare Conference mitwirken. Live-Übertragungen werden über die Website von ORIC zugänglich sein, mit Wiederholungen, die 90 Tage nach den Veranstaltungen verfügbar sind.
- None.
- None.
SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in December:
- 7th Annual Evercore HEALTHCONx Conference – Participating in a fireside chat on Wednesday, December 4, 2024, at 2:35 p.m. ET
- Citi’s 2024 Global Healthcare Conference – Participating in the “Novel Mechanisms in Oncology II” panel on Thursday, December 5, 2024, at 11:00 a.m. ET
Live webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What investor conferences will ORIC Pharmaceuticals attend in December 2024?
When is ORIC's presentation at the Evercore HEALTHCONx Conference?
How long will ORIC's conference webcasts be available for replay?
What panel is ORIC participating in at the Citi Global Healthcare Conference?
